Literature DB >> 20405256

Rehydrated lyophilized rifampicin-loaded mPEG-DSPE formulations for nebulization.

Juma Masoud Abdulla Abdulla1, Yvonne Tze-Fung Tan, Yusrida Darwis.   

Abstract

Rifampicin-loaded nanoparticles were prepared using two different molecular weights of poly-(ethylene oxide)-block-distearoyl phosphatidyl-ethanolamine (mPEG2000-DSPE and mPEG5000-DSPE) polymers. Particle sizes of all formulations studied were in the range of 162-395 nm. The entrapment efficiency (EE) was not affected by the copolymer's molecular weight, and the highest EE (100%) was obtained with drug to copolymer ratio of 1:5. The differential scanning calorimetry (DSC) thermograms showed Tg of rifampicin-loaded PEG-DSPE nanoparticles that shifted to a lower value, indicating entrapment of rifampicin in polymer matrix. The Fourier transformed infrared spectra revealed no chemical interactions between the drug and both copolymers. The in vitro drug release from the formulations occurred over 3 days and followed first-order release kinetic and Higuchi diffusion model. The nebulization of rehydrated lyophilized rifampicin mPEG-DSPE formulations had mass median aerodynamic diameter of 2.6 microm and fine particle fraction of 42%. The aerodynamic characteristic of the preparations was not influenced by the molecular weight of the copolymers. Therefore, it is suggested that both mPEG-DSPE are promising candidates as rifampicin carrier for pulmonary delivery.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20405256      PMCID: PMC2902321          DOI: 10.1208/s12249-010-9428-6

Source DB:  PubMed          Journal:  AAPS PharmSciTech        ISSN: 1530-9932            Impact factor:   3.246


  29 in total

Review 1.  Drug properties affecting aerosol behavior.

Authors:  S Suarez; A J Hickey
Journal:  Respir Care       Date:  2000-06       Impact factor: 2.258

2.  Airways delivery of rifampicin microparticles for the treatment of tuberculosis.

Authors:  S Suarez; P O'Hara; M Kazantseva; C E Newcomer; R Hopfer; D N McMurray; A J Hickey
Journal:  J Antimicrob Chemother       Date:  2001-09       Impact factor: 5.790

Review 3.  A critical review of the probable reasons for the poor variable bioavailability of rifampicin from anti-tubercular fixed-dose combination (FDC) products, and the likely solutions to the problem.

Authors:  S Singh; T T Mariappan; R Shankar; N Sarda; B Singh
Journal:  Int J Pharm       Date:  2001-10-09       Impact factor: 5.875

Review 4.  Targeted delivery of nanoparticles for the treatment of lung diseases.

Authors:  Shirzad Azarmi; Wilson H Roa; Raimar Löbenberg
Journal:  Adv Drug Deliv Rev       Date:  2008-02-06       Impact factor: 15.470

5.  Studies on rifampicin release from ethylcellulose coated nonpareil beads.

Authors:  B Sreenivasa Rao; K V Ramana Murthy
Journal:  Int J Pharm       Date:  2002-01-01       Impact factor: 5.875

6.  Nebulisation of rehydrated freeze-dried beclomethasone dipropionate liposomes.

Authors:  Y Darwis; I W Kellaway
Journal:  Int J Pharm       Date:  2001-03-14       Impact factor: 5.875

7.  Dry powder inhalation of liposomal Ketotifen fumarate: formulation and characterization.

Authors:  M Joshi; A Misra
Journal:  Int J Pharm       Date:  2001-07-31       Impact factor: 5.875

8.  Impaired bioavailability of rifampicin in presence of isoniazid from fixed dose combination (FDC) formulation.

Authors:  C J Shishoo; S A Shah; I S Rathod; S S Savale; M J Vora
Journal:  Int J Pharm       Date:  2001-10-09       Impact factor: 5.875

9.  Liposomes and PLG microparticles as sustained release antitubercular drug carriers--an in vitro-in vivo study.

Authors:  M Dutt; G K Khuller
Journal:  Int J Antimicrob Agents       Date:  2001-09       Impact factor: 5.283

Review 10.  Poly(ethylene oxide)-block-poly(L-amino acid) micelles for drug delivery.

Authors:  Afsaneh Lavasanifar; John Samuel; Glen S Kwon
Journal:  Adv Drug Deliv Rev       Date:  2002-02-21       Impact factor: 15.470

View more
  8 in total

1.  Peptide-micelle hybrids containing fasudil for targeted delivery to the pulmonary arteries and arterioles to treat pulmonary arterial hypertension.

Authors:  Nilesh Gupta; Hany M Ibrahim; Fakhrul Ahsan
Journal:  J Pharm Sci       Date:  2014-09-29       Impact factor: 3.534

2.  Solubilization of beclomethasone dipropionate in sterically stabilized phospholipid nanomicelles (SSMs): physicochemical and in vitro evaluations.

Authors:  Mohanad Naji Sahib; Shaymaa Abdalwahed Abdulameer; Yusrida Darwis; Kok Khiang Peh; Yvonne Tze Fung Tan
Journal:  Drug Des Devel Ther       Date:  2012       Impact factor: 4.162

3.  Rehydrated sterically stabilized phospholipid nanomicelles of budesonide for nebulization: physicochemical characterization and in vitro, in vivo evaluations.

Authors:  Mohanad Naji Sahib; Yusrida Darwis; Kok Khiang Peh; Shaymaa Abdalwahed Abdulameer; Yvonne Tze Fung Tan
Journal:  Int J Nanomedicine       Date:  2011-10-14

Review 4.  Clinical experimentation with aerosol antibiotics: current and future methods of administration.

Authors:  Paul Zarogoulidis; Ioannis Kioumis; Konstantinos Porpodis; Dionysios Spyratos; Kosmas Tsakiridis; Haidong Huang; Qiang Li; J Francis Turner; Robert Browning; Wolfgang Hohenforst-Schmidt; Konstantinos Zarogoulidis
Journal:  Drug Des Devel Ther       Date:  2013-10-02       Impact factor: 4.162

5.  Near-Infrared Heptamethine Cyanine Based Iron Oxide Nanoparticles for Tumor Targeted Multimodal Imaging and Photothermal Therapy.

Authors:  Sejy Lee; Reju George Thomas; Myeong Ju Moon; Hyeong Ju Park; In-Kyu Park; Byeong-Il Lee; Yong Yeon Jeong
Journal:  Sci Rep       Date:  2017-05-18       Impact factor: 4.379

6.  Thermotropic effects of PEGylated lipids on the stability of HPPH-encapsulated lipid nanoparticles (LNP).

Authors:  Poornima Kalyanram; Anu Puri; Anju Gupta
Journal:  J Therm Anal Calorim       Date:  2021-06-26       Impact factor: 4.755

Review 7.  Nanotechnology and pulmonary delivery to overcome resistance in infectious diseases.

Authors:  Fernanda Andrade; Diana Rafael; Mafalda Videira; Domingos Ferreira; Alejandro Sosnik; Bruno Sarmento
Journal:  Adv Drug Deliv Rev       Date:  2013-08-07       Impact factor: 15.470

8.  Biodegradable and Bioactive Carriers Based on Poly(betulin disuccinate-co-sebacic Acid) for Rifampicin Delivery.

Authors:  Daria Niewolik; Barbara Bednarczyk-Cwynar; Piotr Ruszkowski; Alicja Kazek-Kęsik; Grzegorz Dzido; Katarzyna Jaszcz
Journal:  Pharmaceutics       Date:  2022-03-06       Impact factor: 6.321

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.